62.40
Schlusskurs vom Vortag:
$62.69
Offen:
$63.15
24-Stunden-Volumen:
29,909
Relative Volume:
0.20
Marktkapitalisierung:
$688.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.00%
1M Leistung:
+15.24%
6M Leistung:
+164.52%
1J Leistung:
+0.00%
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PVLA
Palvella Therapeutics Inc
|
62.24 | 693.33M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
403.23 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
606.00 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
459.72 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
768.60 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
343.08 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
2025-08-06 | Eingeleitet | Raymond James | Outperform |
2025-07-21 | Eingeleitet | Truist | Buy |
2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
2025-03-26 | Eingeleitet | Stifel | Buy |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
2025-02-05 | Eingeleitet | TD Cowen | Buy |
2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
2018-03-19 | Eingeleitet | Jefferies | Buy |
2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returns2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investmentsWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportWeekly Trend Report & Safe Swing Trade Setups - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthSwing Trade & Technical Pattern Based Buy Signals - newser.com
Tick level data insight on Palvella Therapeutics Inc. volatilityEarnings Beat & Weekly High Potential Stock Alerts - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stockJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Published on: 2025-09-29 15:57:39 - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Trade Analysis Report & Risk Managed Trade Strategies - newser.com
Published on: 2025-09-29 09:58:44 - newser.com
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas - MyChesCo
Published on: 2025-09-29 07:36:24 - newser.com
Equities Analysts Offer Predictions for PVLA FY2028 Earnings - Defense World
Published on: 2025-09-28 21:37:00 - newser.com
Palvella Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Budget Friendly Portfolio - earlytimes.in
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MyChesCo
What analysts say about Palvella Therapeutics Inc stockHealthcare Stock Analysis & Minimal Investment Capital - earlytimes.in
Palvella Expands QTORIN Gel Program for Rare Disease - MSN
Best data tools to analyze Palvella Therapeutics Inc. stockPortfolio Return Report & Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-09-27 05:34:37 - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Analyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan Capital - MarketBeat
Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Chardan Raises Price Target on Palvella Therapeutics to $73 From $60, Keeps Buy Rating - MarketScreener
Goldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics stock price target raised to $70 at Jones Trading - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments By Investing.com - Investing.com South Africa
Stifel Maintains 'Buy' Rating and Raises Price Target for PVLA t - GuruFocus
Stifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00 - MarketBeat
Palvella Therapeutics stock price target raised to $80 by Stifel on new skin treatment - Investing.com Canada
Palvella Therapeutics stock price target raised to $90 from $85 at Oppenheimer - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments - Investing.com Canada
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):